Abbott, R. D., Alt, A., & Trescott, M. (2020). The role of the autoimmune protocol (AIP) diet to improve health related quality of life and disease activity in autoimmune disease: A review of the current clinical evidence. Journal of Evolution and Health, 4(1). https://doi.org/10.15310/j34145989
Ahmad, A., Zaheer, M., & Balis, F. J. (2022, July 27). Baricitinib. StatPearls [Internet]. Retrieved May 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK572064/
Azizov, V., & Zaiss, M. M. (2021). Alcohol consumption in rheumatoid arthritis: A path through the immune system. Nutrients, 13(4), 1324. https://doi.org/10.3390/nu13041324
Benjamin, O., Bansal, P., Goyal, A., & Lappin, S. L. (2022, July 4). Disease modifying anti-rheumatic drugs (DMARD). StatPearls [Internet]. Retrieved May 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK507863/
Bristol Myers Squibb. (2023). Orencia (abatacept) side effects. Retrieved May 30, 2023, from https://www.orencia.com/about-orencia/side-effects-of-orencia
Choi, J., & Fenando, A. (2022, November 11). Sulfasalazine. StatPearls [Internet]. Retrieved May 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK557809/
Cooney, J. K., Law, R.-J., Matschke, V., Lemmey, A. B., Moore, J. P., Ahmad, Y., Jones, J. G., Maddison, P., & Thom, J. M. (2011). Benefits of exercise in rheumatoid arthritis. Journal of Aging Research, 2011, Article 681640. https://doi.org/10.4061/2011/681640
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020). Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clinical Microbiology Reviews, 33(3). https://doi.org/10.1128/cmr.00035-19
Furst, D. E. (2010). The risk of infections with biologic therapies for rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 39(5), 327–346. https://doi.org/10.1016/j.semarthrit.2008.10.002
de Germay, S., Bagheri, H., Despas, F., Rousseau, V., & Montastruc, F. (2019). Abatacept in rheumatoid arthritis and the risk of cancer: A world observational post-marketing study. Rheumatology, 59(9), 2360–2367. https://doi.org/10.1093/rheumatology/kez604
Gerriets, V., Bansal, P., & Khaddour, K. (2022, May 19). Tumor necrosis factor (TNF) inhibitors. StatPearls [Internet]. Retrieved May 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK482425/
Ghlichloo, I., & Gerriets, V. (2020). Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls [Internet]. Retrieved May 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK547742/
Hannoodee, M., & Mittal, M. (2023, January 16). Methotrexate. StatPearls [Internet]. Retrieved May 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK556114/
Herrero-Beaumont, G., Martínez Calatrava, M. J., & Castañeda, S. (2012). Abatacept mechanism of action: Concordance with its clinical profile. Reumatología Clínica (English Edition), 8(2), 78–83. https://doi.org/10.1016/j.reumae.2011.08.004
Hirotsu, C., Tufik, S., & Andersen, M. L. (2015). Interactions between sleep, stress, and metabolism: From physiological to pathological conditions. Sleep Science, 8(3), 143–152. https://doi.org/10.1016/j.slsci.2015.09.002
Kaine, J. L. (2007). Abatacept for the treatment of rheumatoid arthritis: A review. Current Therapeutic Research, 68(6), 379–399. https://doi.org/10.1016/j.curtheres.2007.12.001
Knight, E. L., Jiang, Y., Rodriguez-Stanley, J., Almeida, D. M., Engeland, C. G., & Zilioli, S. (2021). Perceived stress is linked to heightened biomarkers of inflammation via diurnal cortisol in a national sample of adults. Brain, Behavior, and Immunity, 93, 206–213. https://doi.org/10.1016/j.bbi.2021.01.015
Korhonen, R., & Moilanen, E. (2009). Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic & Clinical Pharmacology & Toxicology, 104(4), 276–284. https://doi.org/10.1111/j.1742-7843.2009.00375.x
Martire, L. M., & Helgeson, V. S. (2017). Close relationships and the management of chronic illness: Associations and interventions. American Psychologist, 72(6), 601–612. https://doi.org/10.1037/amp0000066
Maxwell, L., & Singh, J. A. (2009). Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews, 2009(4), Article CD007277. https://doi.org/10.1002/14651858.cd007277.pub2
McMahan, Z. H., & Bingham III, C. O. (2014). Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Research & Therapy, 16(6). https://doi.org/10.1186/s13075-014-0506-0
Mease, P. J., Gottlieb, A. B., van der Heijde, D., FitzGerald, O., Johnsen, A., Nys, M., Banerjee, S., & Gladman, D. D. (2017). Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Annals of the Rheumatic Diseases, 76(9), 1550–1558. https://doi.org/10.1136/annrheumdis-2016-210724
Minihane, A. M., Vinoy, S., Russell, W. R., Baka, A., Roche, H. M., Tuohy, K. M., Teeling, J. L., Blaak, E. E., Fenech, M., Vauzour, D., McArdle, H. J., Kremer, B. H. A., Sterkman, L., Vafeiadou, K., Benedetti, M. M., Williams, C. M., & Calder, P. C. (2015). Low-grade inflammation, diet composition and health: Current research evidence and its translation. British Journal of Nutrition, 114(7), 999–1012. https://doi.org/10.1017/s0007114515002093
Mok, C. C. (2012). Abatacept for systemic lupus erythematosus: The outlook. Expert Opinion on Biological Therapy, 12(12), 1559–1561. https://doi.org/10.1517/14712598.2012.721773
Montastruc, F., Renoux, C., Dell’Aniello, S., Simon, T. A., Azoulay, L., Hudson, M., & Suissa, S. (2019). Abatacept initiation in rheumatoid arthritis and the risk of cancer: A population-based comparative cohort study. Rheumatology, 58(4), 683–691. https://doi.org/10.1093/rheumatology/key352
Nelson, J., Sjöblom, H., Gjertsson, I., Ulven, S. M., Lindqvist, H. M., & Bärebring, L. (2020). Do interventions with diet or dietary supplements reduce the disease activity score in rheumatoid arthritis? A systematic review of randomized controlled trials. Nutrients, 12(10), 2991. https://doi.org/10.3390/nu12102991
NIH News in Health. (2017, February). Do social ties affect our health? U.S. Department of Health and Human Services, National Institutes of Health. https://newsinhealth.nih.gov/2017/02/do-social-ties-affect-our-health
Padda, I. S., Bhatt, R., & Parmar, M. (2023, January 17). Tofacitinib. StatPearls [Internet]. Retrieved May 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK572148/
Pieper, J., Herrath, J., Raghavan, S., Muhammad, K., Vollenhoven, R., & Malmström, V. (2013). CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunology, 14(1), 34. https://doi.org/10.1186/1471-2172-14-34
Preuss, C. V., & Anjum, F. (2022, September 21). Tocilizumab. StatPearls [Internet]. Retrieved May 30, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK570644/
Romeo, J., Wärnberg, J., Nova, E., Díaz, L. E., Gómez-Martinez, S., & Marcos, A. (2007). Moderate alcohol consumption and the immune system: A review. British Journal of Nutrition, 98(S1), S111–S115. https://doi.org/10.1017/s0007114507838049
Sharma, M., & Rush, S. E. (2014). Mindfulness-based stress reduction as a stress management intervention for healthy individuals. Journal of Evidence-Based Complementary & Alternative Medicine, 19(4), 271–286. https://doi.org/10.1177/2156587214543143
Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017). The safety of ingested caffeine: A comprehensive review. Frontiers in Psychiatry, 8(80). https://doi.org/10.3389/fpsyt.2017.00080
Tsuboi, H., Matsumoto, I., Hagiwara, S., Hirota, T., Takahashi, H., Ebe, H., Yokosawa, M., Yagishita, M., Takahashi, H., Kurata, I., Ohyama, A., Honda, F., Asashima, H., Miki, H., Umeda, N., Kondo, Y., Hirata, S., Saito, K., Tanaka, Y., . . . Horai, Y. (2016). Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s Syndrome Endocrinopathy) trial. Modern Rheumatology, 26(6), 891–899. https://doi.org/10.3109/14397595.2016.1158773
U.S. Food and Drug Administration. (2018, February 6). What are “biologics” questions and answers. U.S. Department of Health and Human Services. https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers
Vital, E. M., & Emery, P. (2006). Abatacept in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management, 2(4), 365–375. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936358/
Wang, L., Wang, F.-S., & Gershwin, M. E. (2015). Human autoimmune diseases: A comprehensive update. Journal of Internal Medicine, 278(4), 369–395. https://doi.org/10.1111/joim.12395
Weinblatt, M., Combe, B., Covucci, A., Aranda, R., Becker, J. C., & Keystone, E. (2006). Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis & Rheumatism, 54(9), 2807–2816. https://doi.org/10.1002/art.22070
Weinblatt, M. E., Schiff, M., Valente, R., van der Heijde, D., Citera, G., Zhao, C., Maldonado, M., & Fleischmann, R. (2012). Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis & Rheumatism, 65(1), 28–38. https://doi.org/10.1002/art.37711
You and Your Hormones. (2019, January). Cortisol. Society for Endocrinology. https://www.yourhormones.info/hormones/cortisol/
Zulian, F., Balzarin, M., Falcini, F., Martini, G., Alessio, M., Cimaz, R., Cimino, L., & Zannin, M. E. (2010). Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care & Research, 62(6), 821–825. https://doi.org/10.1002/acr.20115